MA62371A1 - Acide nucléique à codons optimisés codant pour la protéine du facteur fix - Google Patents

Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Info

Publication number
MA62371A1
MA62371A1 MA62371A MA62371A MA62371A1 MA 62371 A1 MA62371 A1 MA 62371A1 MA 62371 A MA62371 A MA 62371A MA 62371 A MA62371 A MA 62371A MA 62371 A1 MA62371 A1 MA 62371A1
Authority
MA
Morocco
Prior art keywords
nucleic acid
acid encoding
codon
optimized nucleic
factor protein
Prior art date
Application number
MA62371A
Other languages
English (en)
Other versions
MA62371B1 (fr
Inventor
Dmitry Valentinovich Morozov
Anna Nikolaevna Strelkova
Pavel Mikhailovich Gershovich
Tatiana Evgenievna Shugaeva
Alexander Vladimirovich Prokofyev
Natalia Aleksandrovna Spirina
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021105703A external-priority patent/RU2831751C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA62371A1 publication Critical patent/MA62371A1/fr
Publication of MA62371B1 publication Critical patent/MA62371B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne les domaines de la génétique, de la thérapie génique et de la biologie moléculaire. Plus particulièrement, la présente invention concerne un acide nucléique isolé à codons optimisés codant pour la protéine fix (facteur ix de coagulation), une cassette d'expression et un vecteur basé sur cette dernière, ainsi qu'un virus recombiné basé sur l'aav5 (virus adéno-associé de sérotype 5) pour augmenter l'expression du gène fix dans des cellules cibles, et son utilisation.
MA62371A 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix MA62371B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021105703A RU2831751C2 (ru) 2021-03-05 Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение
PCT/RU2022/050073 WO2022186734A1 (fr) 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Publications (2)

Publication Number Publication Date
MA62371A1 true MA62371A1 (fr) 2024-03-29
MA62371B1 MA62371B1 (fr) 2025-12-31

Family

ID=83154378

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62371A MA62371B1 (fr) 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Country Status (22)

Country Link
US (1) US20240076691A1 (fr)
EP (1) EP4288549A4 (fr)
JP (1) JP2024509224A (fr)
KR (1) KR20230154067A (fr)
CN (1) CN117716038A (fr)
AR (1) AR125041A1 (fr)
AU (1) AU2022230548A1 (fr)
BR (1) BR112023018003A2 (fr)
CA (1) CA3212809A1 (fr)
CL (1) CL2023002629A1 (fr)
CO (1) CO2023011679A2 (fr)
CR (1) CR20230429A (fr)
EC (1) ECSP23067213A (fr)
IL (1) IL305679A (fr)
JO (1) JOP20230208A1 (fr)
MA (1) MA62371B1 (fr)
MX (1) MX2023010350A (fr)
PE (1) PE20242117A1 (fr)
PY (1) PY2215552A (fr)
TW (1) TW202246505A (fr)
UY (1) UY39659A (fr)
WO (1) WO2022186734A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
US11008561B2 (en) * 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
HUE068603T2 (hu) * 2015-06-23 2025-01-28 Childrens Hospital Philadelphia Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
US11078247B2 (en) * 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
KR102386890B1 (ko) * 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
WO2020084161A1 (fr) * 2018-10-26 2020-04-30 Vrije Universiteit Brussel Nouveaux outils pour améliorer la thérapie génique, et utilisation correspondante
AU2019393880A1 (en) * 2018-12-06 2021-07-15 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor IX

Also Published As

Publication number Publication date
BR112023018003A2 (pt) 2023-12-26
WO2022186734A1 (fr) 2022-09-09
PE20242117A1 (es) 2024-10-28
EP4288549A4 (fr) 2025-06-25
CR20230429A (es) 2024-03-08
US20240076691A1 (en) 2024-03-07
CO2023011679A2 (es) 2024-01-15
UY39659A (es) 2022-09-30
MA62371B1 (fr) 2025-12-31
PY2215552A (es) 2022-09-06
IL305679A (en) 2023-11-01
CN117716038A (zh) 2024-03-15
JOP20230208A1 (ar) 2023-09-05
AU2022230548A1 (en) 2023-09-28
JP2024509224A (ja) 2024-02-29
EP4288549A1 (fr) 2023-12-13
AR125041A1 (es) 2023-05-31
KR20230154067A (ko) 2023-11-07
CA3212809A1 (fr) 2022-09-09
TW202246505A (zh) 2022-12-01
CL2023002629A1 (es) 2024-04-01
ECSP23067213A (es) 2023-10-31
MX2023010350A (es) 2023-09-22

Similar Documents

Publication Publication Date Title
Hayashi et al. An Expression System of Rat Calmodulin Using T7 Phage Promoter inEscherichia coli
Burland et al. Cell type-dependent expression of tubulins in Physarum.
MA58655A1 (fr) Acide nucléique optimisé par codons qui code la protéine smn1
Thorpe et al. Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities
MA62178A1 (fr) Effet synergique de smn1 et mir-23a dans le traitement de l'amyotrophie spinale
Kimura et al. Heterogeneity and differential expression under hypoxia of two-domain hemoglobin chains in the water flea, Daphnia magna
MA56142B1 (fr) Protéine modifiée séparée vp1 de capside de aav5
Terry et al. Properties of avian sarcoma-leukosis virus pp32-related pol-endonucleases produced in Escherichia coli
Xu et al. Effect of promoter, promoter mutation and enhancer on transgene expression mediated by episomal vectors in transfected HEK293, Chang liver and primary cells
MA62371A1 (fr) Acide nucléique à codons optimisés codant pour la protéine du facteur fix
US20050170366A1 (en) Novel hair keratin-associated proteins
Pittelkow et al. Human and porcine aminoacylase I overproduced in a baculovirus expression vector system: evidence for structural and functional identity with enzymes isolated from kidney
Fu et al. Asp-ase activity of the opossum granzyme B supports the role of granzyme B as part of anti-viral immunity already during early mammalian evolution
Day et al. Purification and molecular-cloning of human apolipoprotein F
Kern et al. The outer kinetochore protein KNL-1 contains a defined oligomerization domain in nematodes
MA68435A1 (fr) Acide nucléique isolé codant pour une protéine de fusion à base de fviii-bdd et d'un peptide de signal hétérologue
MA64618A1 (fr) Protéine modifiée séparée vp1 de capside aav9
Kádas et al. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity
MA68586A1 (fr) Acide nucléique à codons optimisés codant pour fviii-bdd
Cabral et al. Dataset on recombinant expression of an ancient chitinase gene from different species of Leishmania parasites in bacteria and in Spodoptera frugiperda cells using baculovirus
Raja et al. Loss of direct binding of Leishmania profilin with actin adversely affected its functions and interactions with other cellular proteins
Jayakumar et al. Functional analysis of Drosophila melanogaster hexokinase Hex‐A locus: multiple Initiator‐like elements enhance DPE containing promoter activity
Zhang et al. Guinea pig serum L-asparaginase: purification, and immunological relationship to liver L-asparaginase and serum L-asparaginases in other mammals
TAKAHASHI et al. Morphological changes of the lateral projections of myosin filament
Patnaik Structural and functional studies on vaccinia virus E3 protein